Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
150
resultados
Última actualización
04/07/2025 [07:37:00]
Resultados 75 a 100 de 150
Resumen de: US2025169721A1
A notification device is provided for presenting blood glucose level information for a tracked individual. The notification device is configured to receive first and second blood glucose level information from first and second tracking devices associated with different manufacturers. The first and second blood glucose level information each include at least one of a blood glucose level or a first or second derivative for the blood glucose level as a function of time. The notification device comprises a screen, processor(s), and memory device(s) containing computer readable code. When executed by the processor(s), the computer readable code is configured to cause the processor(s) to receive the first and/or the second blood glucose level information and cause presentation of the first and/or the second blood glucose level information on the screen. The first and second tracking devices are each a continuous blood glucose monitor.
Resumen de: US2025169764A1
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting al
Resumen de: US2025170330A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: US2025166254A1
An integrated system for the monitoring and treating diabetes is provided, including an integrated receiver/hand-held medicament injection pen, including electronics, for use with a continuous glucose sensor. In some embodiments, the receiver is configured to receive continuous glucose sensor data, to calculate a medicament therapy (e.g., via the integrated system electronics) and to automatically set a bolus dose of the integrated hand-held medicament injection pen, whereby the user can manually inject the bolus dose of medicament into the host. In some embodiments, the integrated receiver and hand-held medicament injection pen are integrally formed, while in other embodiments they are detachably connected and communicated via mutually engaging electrical contacts and/or via wireless communication.
Resumen de: WO2025104963A1
This blood sugar level measuring device comprises: a light output unit that includes a green light source that outputs incident light; a light detection unit that detects transmitted light that has passed through a living body; and a computation unit that calculates the blood sugar level of the living body. In the spectrum of the incident light, the center wavelength is located at 430-580 nm, the intensity at 600-615 nm is at least 0.01% of the intensity at the center wavelength, and the intensity at 480-515 nm is at least 1% of the intensity at the center wavelength. The light detection unit includes a first light detector having a first detection wavelength range of 460-535 nm and a second light detector having a second detection wavelength range of at least 580 nm. The computation unit calculates the blood sugar level of the living body on the basis of the intensity of the transmitted light detected by the first light detector and the intensity of the transmitted light detected by the second light detector.
Resumen de: WO2025102531A1
A protection device for the front end of an insulin pen needle, comprising: a housing (1); a needle hub (2), which is fixed in the housing (1), the needle hub (2) being provided with an injection needle extending out of the head end of the housing (1); a sliding fastener (3), which is sleeved on the needle hub (2) and is in sliding fit with the needle hub (2), the outer surface of the sliding fastener (3) being provided with a snap-fit portion (31); and a needle tip protective sleeve (4), which is slidably provided in the housing (1), an elastic piece (41) being provided on single side of the inner wall of the needle tip protective sleeve (4), and a spring (5) is clamped between the needle tip protective sleeve (4) and the needle hub (2). When the insulin pen needle is in an injection state, the needle tip protective sleeve (4) presses the spring (5) to retract into the housing (1), such that the needle tip protective sleeve (4) is sleeved on the sliding fastener (3), and in the case that the elastic piece (41) slides to the position of the snap-fit portion (31), the elastic piece (41) hooks the snap-fit portion (31), so as to expose the needle tip of the injection needle (21). When the insulin pen needle is in a retraction state, the needle tip protective sleeve (4) extends out of the housing (1) under the elastic force of the spring (5) and drives the sliding fastener (3) to withdraw from the needle hub (2); the sliding fastener (3) is offset with the needle hub (2) under t
Resumen de: AU2025203154A1
Abstract: Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.
Resumen de: AU2025203062A1
The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
Resumen de: US2025160749A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: US2025160748A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: US2025160703A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Resumen de: WO2025106335A1
Techniques for generating and modifying user interfaces for displaying glucose sensor data are disclosed. Initial or first sensor data is displayed with a first formatting until it is dynamically changed to a second formatting that de-emphasizes the data while new sensor data is concurrently displayed with the first formatting to emphasize the new sensor data relative to the older / first sensor data.
Resumen de: WO2025106281A1
Sensor systems are provided that include (i) a sensor configured to obtain sensor data indicative of an analyte level of a user's body, (ii) a first transmitter patch configured in size and shape to overlay the sensor during a first time period of use, (iii) a second transmitter patch configured in size and shape to overlay the sensor during a second time period of use. First sensor data is transmitted from the sensor to the first transmitter patch corresponding to the first time period and second sensor data is transmitted from the sensor to the second transmitter patch corresponding to the second time period. The first transmitter patch can be replaced by the second transmitter patch without removing the sensor.
Resumen de: WO2025106280A1
Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.
Resumen de: WO2025102533A1
An insulin pen needle front-end protection apparatus, comprising a housing (1), the housing(1) being provided with a first through hole (11) in a head end; a needle base (2) fixedly connected to a tail end of the housing (1), the needle base (2) being provided with a protruding portion (21) extending towards the head end of the housing (1), and an injection needle (22) extending out of the first through hole (11) being arranged on the protruding portion (21); a sliding buckle (3) sleeved on the protruding portion (21), a constriction structure being arranged at a tail end of the sliding buckle (3), and a head end of the sliding buckle (3) being provided with a second through hole (31); and a needle tip protection sleeve (4) at least partially arranged in the housing (1), a spring (5) being clamped between a tail end of the needle tip protection sleeve (4) and the needle base (2), a head end of the needle tip protection sleeve (4) extending out of the first through hole (11) and being provided with a third through hole (41), and at least two clamping buckles (42) being arranged on an inner wall of the needle tip protection sleeve (4).
Resumen de: WO2025102900A1
A non-invasive blood glucose measurement system (100), comprising an optical transceiver assembly (110); a filtering unit (120), electrically connected to the optical transceiver assembly (110); and a micro-processing unit (130), electrically connected to the filtering unit (120). The optical transceiver assembly (110) comprises: at least two light sources (111), a first detector (112) and at least two second detectors (113), the at least two light sources (111) being used for emitting laser detection signals, and the first detector (112) and the at least two second detectors (113) being used for detecting returned laser signals. The at least two light sources (111) are provided around the first detector (112); the at least two second detectors (113) are provided around the light source (111); and a light detection surface of the first detector (112), light detection surfaces of the at least two second detectors (113), and light emergent surfaces of the at least two light sources (111) face the same direction. Data analysis and processing of short-path optical signals and long-path optical signals can obtain an optical concentration difference between a dark portion and a light portion of skin, thereby reducing the influences caused by melanin and skin, and improving the accuracy in non-invasive blood glucose measurement.
Resumen de: WO2025102532A1
Provided is an insulin pen needle rear end protection device, which comprises: a housing (1), wherein the tail end of the housing (1) is arranged to be connected with an insulin injection pen; a needle holder (2) fixed in the housing (1), wherein an injection needle extending to the tail end of the housing (1) is arranged on the needle holder (2), a guide groove (22) is formed in the side wall of the needle holder (2), and a protruding block (23) is further arranged on the inner surface of the side wall of the needle holder (2); and a rear needle protective sleeve (3) arranged in the needle holder (2) in a penetrating manner, wherein a spring (4) is clamped between the rear needle protective sleeve (3) and the needle holder (2), and a positioning column (31) and an elastic clamping jaw (32) are arranged on the outer surface of the rear needle protective sleeve (3). When the insulin pen needle is connected to the injection pen, the rear needle protective sleeve (3) is compressed into the needle holder (2), the positioning column (31) moves in the guide groove (22) to a first position, and the elastic clamping jaw (32) is located on the side of the protruding block (23) away from the tail end of the needle holder (2); when the insulin pen needle is separated from the injection pen, the positioning column (31) moves to a second position along the guide groove (22) under the acting force of the spring (4), such that the rear needle protective sleeve (3) pops up, and the elastic c
Resumen de: US2025166780A1
Systems and methods are disclosed that employ several or numerous factors in the determination of a glycemic urgency index (GUI), which may be based on a measured blood glucose level as well as other factors. The other factors may include time derivatives of the glucose level and/or other factors, e.g., user-entered data, data measured by other sensors or received from a network source, or historical data. The GUI is then presented to the user in an interesting way, e.g., via a background color or other inconspicuous notifier, e.g., on a mobile device such as a smart phone. The GUI may also be employed in the triggering of actionable alerts and alarms on an electronic device for the user. The GUI, or another index calculated from combinations of the variables and parameters described, may further be employed to drive a medicament delivery device such as a pump.
Resumen de: US2025160695A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160692A1
Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and/or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.
Resumen de: US2025160694A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Resumen de: US2025160697A1
Certain aspects of the present disclosure relate to a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.
Resumen de: WO2025106990A1
Integrated patch-pump devices to deliver drugs, e.g., macromolecular drugs that are difficult to deliver through an oral pathway and/or that require transdermal delivery. Embodiments are slim, powerless, painless, and relatively inexpensive. The microfluidic pump is used to drive the fluid flow powered by pressurized air or the user's pulse, and the microneedle array is used to inject the fluid through the skin painlessly. The flow rate generally positively correlates with the actuation pressure. For devices with wider flow channels, the flow rate generally negatively correlates with the actuation frequency, whereas the flow rate increases and then decreases with increasing actuation frequency for devices with narrower flow channels. This property of these devices is beneficial in insulin delivery because the demand for insulin is generally reduced in vigorous exercise (with elevated heart rate/ actuation frequency) and is increased in hypertension patients (with elevated blood/actuation pressure).
Resumen de: US2025160696A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Nº publicación: US2025160642A1 22/05/2025
Solicitante:
DEXCOM INC [US]
Dexcom, Inc
Resumen de: US2025160642A1
In some example embodiments, there is provided a method, which includes sending a message to a server, wherein the message includes a request for a share code to enable another user to access, via a first computer, analyte data obtained from a host-patient associated with a receiver and/or an analyte report for the host-patient associated with the receiver; receiving, in response to the sending, the share code generated by the server, wherein the share code comprises a checksum portion, a password portion, and an identifier portion indicative of the host-patient; generating a user interface view including the share code; and displaying the user interface view including the share code, wherein the share code enables the other user to access, via the first computer, the analyte data and/or the analyte report. Related systems, methods, and articles of manufacture are also disclosed.
BOPI
Sede Electrónica
